Beth Israel Deaconess Medical Center
330 Brookline Avenue
124 articles about Beth Israel Deaconess Medical Center
As Omicron dominates the COVID-19 landscape, scientists are urging the FDA to reconsider how the agency defines immune responses.
Drug companies have been suggesting that booster shots will be needed. However, it is up to the CDC's recommendation if booster shots are necessary.
NanoView Biosciences Launches EPIC Study to Investigate Impact of Exosome-Associated Biomarkers for Immuno-Oncology
NanoView Biosciences Inc. ("NanoView"), a leading biomarker characterization company in the emerging field of extracellular vesicle biology, today announced a collaboration agreement with Beth Israel Deaconess Medical Center ("BIDMC") to study the involvement of biomarkers
Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development
Research well underway as Janssen scientists collaborate with leading virology laboratory led by Dan Barouch, M.D., Ph.D.
Study Identifies the Molecular Mechanisms by which Noonan Syndrome RAF1 mutations cause Cardiac Hypertrophy
Investigators from the Masonic Medical Research Institute, Weill Cornell Medicine and Beth Israel Deaconess Medical Center have identified the molecular mechanisms by which RAF1 mutations in patients with Noonan Syndrome cause hypertrophic cardiomyopathy, a dangerous thickening of the heart muscle that can lead to heart failure and death.
Synlogic, Inc. (Nasdaq: SYBX), a biology-focused clinical-stage company focused on living medicines, has just today announced that effective immediately, Aoife Brennan, M.B., B.Ch., has been appointed as president and chief executive officer (CEO).
Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys
Gilead Sciences, Inc. announced results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating the combination of a proprietary investigational oral toll-like receptor 7 (TLR7) agonist, GS-9620, and a proprietary investigational broadly neutralizing antibody (bNAb), PGT121, as part of an HIV eradication strategy.
Mustang Bio Announces License Agreement With Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies
Under the deal, technologies related to the development of off-the-shelf CAR T, as well as CRISPR/Cas9 gene editing platforms, will be utilized in conjunction with Mustang’s CAR T cell therapies.
New Tool Can Predict Individual’s Risk Of Psychotic Disorders, Beth Israel Deaconess Medical Center Study
New Electric Mesh Device Gives The Heart An Electromechanical Hug, Beth Israel Deaconess Medical Center Study
Novel Method For Extending The Life Of Implantable Devices In Situ Developed, Beth Israel Deaconess Medical Center Scientists Report
A Single Drink Can Temporarily Up Your Heart Attack And Stroke Risk, Beth Israel Deaconess Medical Center Research Finds
A New Hospital Supercomputer Predicts The Probable Time Of Your Death, Beth Israel Deaconess Medical Center Study
Quanterix And Beth Israel Deaconess Medical Center Publish Study On The Development And Validation Of Digital Elisas For Ultrasensitive Detection And Quantification Of C. Difficile Toxins In Stool
Strong Link Between Delirium And Inflammation In Older Patients Found, Beth Israel Deaconess Medical Center Reveals
Beth Israel Deaconess Medical Center Scientists Develop Antibody To Treat Traumatic Brain Injury And Prevent Long-Term Neurodegeneration
Long-Term Exposure To Air Pollution May Shrink Your Brain, Beth Israel Deaconess Medical Center Study
Already-Approved FDA Drug May Cure Obesity Too, Joslin Diabetes Center And Beth Israel Deaconess Medical Center Study